- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.03. | Ocugen eye disease gene therapy hits ph. 2 targets but underwhelms investors | ||
| 24.03. | Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream | ||
| 24.03. | Innovent sees path to China approval after eye disease drug matches Eylea in phase 3 | ||
| 24.03. | Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos | ||
| 23.03. | Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific | ||
| 23.03. | Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear | ||
| 23.03. | Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push | ||
| 20.03. | Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial | ||
| 20.03. | Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle | ||
| 20.03. | Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral | ||
| 19.03. | Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure | ||
| 19.03. | Pfizer adds to Seagen scrap heap with another early cancer candidate cull | ||
| 19.03. | Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector | ||
| 19.03. | Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals | ||
| 18.03. | Rare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and Congress | ||
| 18.03. | Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome | ||
| 18.03. | Crossbow hits $77M series B round to bankroll quiver of T-Bolts | ||
| 17.03. | Xaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for' | ||
| 17.03. | J&J changes New York state of mind, closing JLABS site after 8 years | ||
| 17.03. | Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30% | ||
| 17.03. | FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings | ||
| 17.03. | Pfizer's hotly tipped breast cancer prospect delivers phase 2 win | ||
| 16.03. | Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development | ||
| 16.03. | Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years | ||
| 16.03. | Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.